OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
July 27, 2023
Janssen has received a positive opinion from the EMA for two novel bispecific antibodies, TALVEY (talquetamab) and TECVAYLI (teclistamab), which the company is developing to treat blood cancer.
July 24, 2023
Newly launched Crossbow Therapeutics will work to advance a novel class of antibody therapies for treating cancers.
July 18, 2023
The goal for Upperton is to become fully operational by Q4 of 2023 for development and non-GMP manufacturing and a target start of GMP operations in January 2024.
Jeff Fischer, co-founder and president of Longhorn Vaccines and Diagnostics, discusses the history and ongoing development of both protein- and mRNA-based vaccines.
July 11, 2023
Webinar Date/Time: Tue, Aug 8, 2023 11:00 AM EDT
July 07, 2023
Thermo Fisher Scientific’s new tumoroid culture medium kit is designed to help cancer researchers better model the disease.
Eurofins Genomics Blue Heron’s novel mRNA synthesis service is designed for customizable applications.
July 06, 2023
Chime Biologics, Leads Biolabs, and BeiGene have formed a three-way collaboration to advance the development and global manufacturing of Leads Biolabs’ lead mAb candidate, LBL-007.
July 03, 2023
FDA’s new guidance on in-vitro permeation test studies published in October 2022 gives technical and statistical requirements for conducting these tests to compare topical generic drugs with their reference products.
Sample dilution, sensitivity, excipient interference, and containment are key issues that must be addressed.